Literature DB >> 10399095

Intracellular degradation of fluorescent glycolipids by lysosomal enzymes and their activators.

L Madar-Shapiro1, M Pasmanik-Chor, T Dinur, A Dagan, S Gatt, M Horowitz.   

Abstract

Fluorescent glycolipids were utilized for detection of the intracellular, activator-dependent, activities of beta-glucocerebrosidase and arylsulphatase A. Activities were measured in primary skin fibroblasts from normal individuals, from patients with Gaucher disease who had mutations within the beta-glucocerebrosidase gene, and from a prosaposin-deficient patient. Fluorescent microscopy demonstrated that glucosylceramide or sulphatide labelled with a fluorescent probe (lissamine-rhodamine) were endocytosed and reached the lysosomes. There, in the presence of active enzyme and the corresponding saposin, they were hydrolysed to fluorescent ceramide, which changed its intracellular localization. When these substrates were labelled with pH-sensitive lissamine-rhodamine, which loses its fluorescence at neutral or alkaline pH, the transport of the product, i.e. fluorescent ceramide, from the lysosomes resulted in disappearance of the cellular fluorescence. In cells of patients having mutations within the genes encoding the glucocerebrosidase or the prosaposin, there was a considerable reduction in the intracellular rate of substrate hydrolysis that could be followed by fluorescence microscopy or measured quantitatively in cell extracts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399095     DOI: 10.1023/a:1005573812430

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  27 in total

1.  METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

Authors:  R O BRADY; J N KANFER; D SHAPIRO
Journal:  Biochem Biophys Res Commun       Date:  1965-01-18       Impact factor: 3.575

2.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.

Authors:  A Zimran; T Gelbart; B Westwood; G A Grabowski; E Beutler
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

3.  Hematologically important mutations: Gaucher disease.

Authors:  E Beutler; T Gelbart
Journal:  Blood Cells Mol Dis       Date:  1998-03       Impact factor: 3.039

4.  Differential expression of the human glucocerebrosidase-coding gene.

Authors:  O Reiner; M Horowitz
Journal:  Gene       Date:  1988-12-20       Impact factor: 3.688

5.  [A cerebrosidesulfatase from swine kidney].

Authors:  E Mehl; H Jatzkewitz
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1964

6.  Proteolytic processing patterns of prosaposin in insect and mammalian cells.

Authors:  T Leonova; X Qi; A Bencosme; E Ponce; Y Sun; G A Grabowski
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

7.  Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype.

Authors:  A Abrahamov; D Elstein; V Gross-Tsur; B Farber; Y Glaser; I Hadas-Halpern; S Ronen; M Tafakjdi; M Horowitz; A Zimran
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

8.  Gaucher disease: gene frequencies in the Ashkenazi Jewish population.

Authors:  E Beutler; N J Nguyen; M W Henneberger; J M Smolec; R A McPherson; C West; T Gelbart
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

9.  Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene.

Authors:  D Schnabel; M Schröder; W Fürst; A Klein; R Hurwitz; T Zenk; J Weber; K Harzer; B C Paton; A Poulos
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

10.  Identification of the neurotrophic factor sequence of prosaposin.

Authors:  J S O'Brien; G S Carson; H C Seo; M Hiraiwa; S Weiler; J M Tomich; J A Barranger; M Kahn; N Azuma; Y Kishimoto
Journal:  FASEB J       Date:  1995-05       Impact factor: 5.191

View more
  3 in total

1.  Use of lissamine rhodamine ceramide trihexoside as a functional assay for alpha-galactosidase A in intact cells.

Authors:  Christine R Kaneski; Raphael Schiffmann; Roscoe O Brady; Gary J Murray
Journal:  J Lipid Res       Date:  2010-06-06       Impact factor: 5.922

Review 2.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

3.  Preimplantation diagnosis of a lysosomal storage disorder by in situ enzymatic activity: 'proof of principle' in acid sphingomyelinase-deficient mice.

Authors:  A Butler; S C Henderson; R E Gordon; A Dagan; S Gatt; E H Schuchman
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.